Literature DB >> 35464268

Surgery is the means of treatment, but high-quality survival is the ultimate goal.

Penglei Ge1, Yang Wu1.   

Abstract

Entities:  

Year:  2022        PMID： 35464268      PMCID： PMC9023842          DOI： 10.21037/hbsn-2022-05

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  10 in total

1.  Early survival and safety of ALPPS: first report of the International ALPPS Registry.

Authors:  Erik Schadde; Victoria Ardiles; Ricardo Robles-Campos; Massimo Malago; Marcel Machado; Roberto Hernandez-Alejandro; Olivier Soubrane; Andreas A Schnitzbauer; Dimitri Raptis; Christoph Tschuor; Henrik Petrowsky; Eduardo De Santibanes; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2014-11       Impact factor: 12.969

Review 2.  Preparing for liver surgery with "Alphabet Soup": PVE, ALPPS, TAE-PVE, LVD and RL.

Authors:  DaeHee Kim; Joshua Cornman-Homonoff; David C Madoff
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 3.  Portal vein embolization for hepatocellular carcinoma.

Authors:  Junichi Shindoh; Ching-Wei D Tzeng; Jean-Nicolas Vauthey
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

4.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Authors:  Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

5.  ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy.

Authors:  Albert Chan; Wei Yi Zhang; Kenneth Chok; Jeff Dai; Ren Ji; Crystal Kwan; Nancy Man; Ronnie Poon; Chung Mau Lo
Journal:  Ann Surg       Date:  2021-05-01       Impact factor: 12.969

Review 6.  The role of associating liver partition and portal vein ligation for staged hepatectomy in the management of patients with colorectal liver metastasis.

Authors:  Juan Glinka; Victoria Ardiles; Juan Pekolj; Eduardo de Santibañes; Martin de Santibañes
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

7.  Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report.

Authors:  M Makuuchi; B L Thai; K Takayasu; T Takayama; T Kosuge; P Gunvén; S Yamazaki; H Hasegawa; H Ozaki
Journal:  Surgery       Date:  1990-05       Impact factor: 3.982

8.  Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry.

Authors:  Yoji Kishi; Eddie K Abdalla; Yun Shin Chun; Daria Zorzi; David C Madoff; Michael J Wallace; Steven A Curley; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

9.  Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center.

Authors:  Fabrizio Panaro; Fabio Giannone; Benjamin Riviere; Olivia Sgarbura; Caterina Cusumano; Emmanuel Deshayes; Francis Navarro; Boris Guiu; Francois Quenet
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

10.  How should liver hypertrophy be stimulated? A comparison of upfront associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and portal vein embolization (PVE) with rescue possibility.

Authors:  Ernesto Sparrelid; Kristina Hasselgren; Bård Ingvald Røsok; Peter Nørgaard Larsen; Nicolai Aagaard Schultz; Ulrik Carling; Eva Fallentin; Stefan Gilg; Per Sandström; Gert Lindell; Bergthor Björnsson
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 7.293
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.